55736-69-1

Usage

Preparation

Preparation by diazotization of 2-amino-6-bromoacetophenone, followed by hydrolysis of the obtained diazonium salt (50%).

InChI:InChI=1/C8H7BrO2/c1-5(10)8-6(9)3-2-4-7(8)11/h2-4,11H,1H3

Upstream product

• 35065-86-2 3-bromophenyl acetate 
• 1241953-60-5 1-[2-bromo-6-(methoxymethoxy)phenyl]ethanone 

Downstream Products

• 945724-02-7 (E)-1-(4-bromo-2-hydroxyphenyl)-3-(dimethylamino)prop-2-en-1-one 
• 1441774-59-9 C₁₈H₁₇BrO₅ 
• 1441772-18-4 5-bromo-3-hydroxy-2-(2,4,5-trimethoxyphenyl)-4H-chromen-4-one 
• 1401669-21-3 2-(2-aminothiazol-4-yl)-3-bromophenol 

Relevant academic research and scientific papers

NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desat- urase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

CHROMANE ANTAGONIST OF THE H-3 RECEPTOR

This invention is directed to a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula (I), a process of preparation of a compound of formula (I), a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula (I) as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula (I) as described above.